Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial.
Saved in:
| Title: | Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial. |
|---|---|
| Authors: | Ou, Jianjun, Smith, Robert C., Tobe, Russell H., Lin, Jingjing, Arriaza, Jen, Fahey, Jed W., Liu, Ruiting, Zeng, Ying, Liu, Yanan, Huang, Lian, Shen, Yidong, Li, Yamin, Cheng, Daomeng, Cornblatt, Brian, Davis, John M., Zhao, Jingping, Wu, Renrong, Jin, Hua |
| Source: | Journal of Autism & Developmental Disorders. Feb2024, Vol. 54 Issue 2, p628-641. 14p. |
| Subjects: | Research funding, Placebos, Autism, Sulfur compounds, Blind experiment, Antipsychotic agents, Randomized controlled trials, Behavior, Age distribution, Drug efficacy, Attitudes of medical personnel, Asperger's syndrome, Caregiver attitudes, Child behavior, Drug tolerance, Evaluation, Children |
| Geographic Terms: | China |
| Abstract: | Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Autism & Developmental Disorders is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 01623257 |
| DOI: | 10.1007/s10803-022-05784-9 |
